FBXO32 and sarcopenia: As nutritional supplementation, L-carnitine treatment was applied in cachectic mice resulting in increased protein levels of phosphorylated FOXO3 and decreased levels of ATROGIN-1 and MURF1 in vivo, suggesting its mediation via the PI3K/AKT pathway and resulting in more active AKT as a potential target in sarcopenia treatment (Figure 2).